Here, our data support the idea that an agonist of TMPRSS2/ACE2 may improve COVID-19 death incidence in men; however, it may not be proper to administer it in female patients because ACE2 expression is positively associated with female COVID-19 death. This evidence concerns the gene ACE2 and COVID-19.